Arcus Says Initial Data From The Arc-20 Study Of Casdatifan Plus Cabozantinib Showed Nearly Half Of Patients With Metastatic Kidney Cancer Had A Confirmed Response

Arcus Biosciences Inc RCUS:

• INITIAL DATA FROM THE ARC-20 STUDY OF CASDATIFAN PLUS CABOZANTINIB SHOWED NEARLY HALF OF PATIENTS WITH METASTATIC KIDNEY CANCER HAD A CONFIRMED RESPONSE

• ARCUS BIOSCIENCES INC - ARC-20 STUDY SHOWS 46% RESPONSE RATE IN METASTATIC KIDNEY CANCER